Market Overview

My goal is to be on stage with my computer and let you
see my screen and make sure you know what buttons to
press, where you’re getting in & out, how to calculate
risk, your targets — all of those things.
It’s real-life trading. Make sure you sign up!
- Jerremy Newsome
GET TICKETS

Cesca Receives Approval for Medicare Coverage

Share:

Cesca Therapeutics Inc. (NASDAQ: KOOL), an autologous cell-based regenerative medicine company, today announced that it has received approval for Medicare coverage for the investigational device exemption ("IDE") study protocol entitled: Critical Limb Ischemia Rapid Delivery by SurgWerks-CLI Kit and VXP System ("CLIRST III") from the Centers for Medicare and Medicaid Services ("CMS"), a federal agency within the United States Department of Health and Human Services. According to the official correspondence from CMS, Cesca's IDE study was consistent with conditions specified in the IDE regulations and was therefore approved for Medicare coverage. This approval extends coverage across all Medicare administrative regions.

"We are very pleased with the CMS's decision to approve our potentially life changing, pivotal clinical study in critical limb ischemia ("CLI") for Medicare reimbursement," said Robin Stracey, Chief Executive Officer of Cesca. He added, "Achieving Medicare reimbursement is a significant milestone. Medicare reimbursement will further the Company's efforts to find an effective treatment for CLI, the most severe form of peripheral arterial disease ("PAD"). Often associated with chronic foot and leg ulcers and leading to approximately two hundred thousand major and minor amputations per year, Medicare reimbursement will help the Company reduce the cost of our clinical trial as the team at Cesca works toward fulfilling a major unmet medical need."

Posted-In: News FDA Press Releases

 

Related Articles (KOOL)

View Comments and Join the Discussion!
Lightning Fast
Market News Service
$199 Free 14 Day Trial

Tekla Transitions to Trimble Brand

Accelerate Diagnostics Reports Positive Results From Pilot Study of Its Investigational ID/AST System and Blood Culture Assay Kit and Initiation of Trial to Support FDA Clearance